Skip to main content
Evidence Snapshot

Melatonin receptor type 1A

CHEMBL1945 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:13Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1945
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Melatonin receptor type 1A as ChEMBL target CHEMBL1945, mapped to UniProt P48039. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Melatonin receptor type 1A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1945
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P48039
Melatonin receptor type 1A
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Melatonin receptor type 1A matters

As of 2026-09-13

Melatonin receptor type 1A is reviewed as Melatonin receptor type 1A (UniProt P48039); the current evidence base includes 10 approved drugs, 1444 compounds, and 321 assays, with lead potency reaching pChEMBL 11.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 10 approved drugs, 1444 compounds, and 321 assays for this target. The dominant activity type is KI. CHEMBL132802 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL132802 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
10 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Melatonin receptor type 1A matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P48039, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1444
Total Compounds
321
Total Assays
10
Approved Drugs
IC50: 248.0, KI: 1244.0, EC50: 251.0, KD: 2.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL132802
 11.0 Ki —
No preferred name
CHEMBL330137
 11.0 Ki —
No preferred name
CHEMBL287560
 11.0 Ki —
No preferred name
CHEMBL1774529
 11.0 Ki —
No preferred name
CHEMBL336054
 10.9 Ki —

Approved Drugs

Structure Compound First Approval
AGOMELATINE
CHEMBL10878
 2009
MELATONIN
CHEMBL45
 2007
RAMELTEON
CHEMBL1218
 2005
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:13Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1945